drug
triamcinolone acetonide Rising
Marketedupdated 3mo agoby Rising Pharma Holdings Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugKenalog17 co-mentions · 17 sources
- drugtriamcinolone acetonide ER17 co-mentions · 17 sources
- drugTRIAMCINOLONE ACETONIDE17 co-mentions · 17 sources
- tagApproval12 co-mentions · 6 sources
- tagRecall11 co-mentions · 11 sources
- drugtestosterone10 co-mentions · 10 sources
- drugTestim10 co-mentions · 10 sources
- drugVogelxo10 co-mentions · 10 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 20 approved and 47 investigational indications.
indications
investigational
Psoriasis
all catalysts(6)
approval · 6
Jun 1, 2009
approval
TRIAMCINOLONE ACETONIDE — FDA approval
triamcinolone acetonide Rising
→
Mar 18, 2011
approval
TRIAMCINOLONE ACETONIDE — FDA approval
triamcinolone acetonide Rising
→
Nov 13, 2012
approval
TRIAMCINOLONE ACETONIDE — FDA approval
triamcinolone acetonide Rising
→
Oct 3, 2019
approval
TRIAMCINOLONE ACETONIDE — FDA approval
triamcinolone acetonide Rising
→
Oct 8, 2025
approval
TRIAMCINOLONE ACETONIDE — FDA approval
triamcinolone acetonide Rising
→
Oct 17, 2025
approval
TRIAMCINOLONE ACETONIDE — FDA approval
triamcinolone acetonide Rising
→
Trials studying triamcinolone acetonide Rising
- phase2A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip
- phase2Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
- phase4Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout
- phase1Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 2, 2027
255 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Apr 16, 2040formulationUS 12419833
- May 2, 2034formulationUS 9937075
- Nov 8, 2033method-of-use (U-3234)US 9636332
- Aug 4, 2031formulationUS 88284405.0y
- Aug 4, 2031method-of-use (U-2151)US 95550485.0y
- Dec 17, 2029formulationUS 81289603.3y
- Mar 10, 2029method-of-use (U-1257)US 82118802.6y
- May 2, 2027method-of-use (U-3234)US 8636713255d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that